Eyenovia Announces Positive Study Results Demonstrating its Optejet Delivery Technology Reduces Conjunctival Cell Toxicity From Preserved Ophthalmic Solutions to a Level Comparable With Non-Preserved Solutions
Eyenovia, Inc. recently announced positive results from a research study conducted in collaboration with Dr. Pedram Hamrah, Interim Chairman of Ophthalmology at Tufts Medical Center, which evaluated the ocular surface damage from Latanoprost+Benzalkonium Chloride (BAK) treatment administered via Optejet versus Latanoprost+BAK administered via standard eye drops.
Preservatives in topical ophthalmic drugs administered via standard eye drops help ensure sterility of the product and increase shelf-life. However, patients on chronic topical ophthalmic drug treatments often display long-term ocular adverse effects due to toxicity from over-exposure to preservatives.
“Long-term use of ophthalmic eye drops with preservatives is a significant clinical concern and therapeutic burden,” remarked Professor Robert Weinreb, MD, Chair of Ophthalmology at the University of California, San Diego, and member of the Eyenovia Scientific Advisory Board. “For patients with chronic conditions such as glaucoma, this is a major concern when treatment with topical medications can last a lifetime.”
Per the study design, conjunctival epithelial cells were exposed to drug by standard drop or Optejet microdose technology. Cell-based assays were then conducted to assess cell viability, cytotoxicity, apoptosis, ROS generation, and ATP generation (metabolic activity).
The study found that human conjunctival epithelial cells tolerated Latanoprost+BAK treatment administered via Optejet technology significantly better than Latanoprost+BAK administered via standard drops. Optejet technology had similar results to both latanoprost without BAK and no-treatment controls with respect to all four measures.
Beth Scott, OD, Vice President of Regulatory and Medical Affairs at Eyenovia, commented “It is well established that BAK preservative in most preserved eye drops causes damage to the ocular surface, including the cornea epithelium, conjunctiva, and neural cells. The current study successfully proved that due to the much smaller volume of drug and preservatives required with the Optejet device, the level of ocular surface damage due to preservative toxicity would be minimal. This study adds to the body of evidence supporting our breakthrough Optejet technology.”
Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia, and myopia progression. For more information, visit Eyenovia.com.
Total Page Views: 951
